Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, represents a valuable laboratory reagent extensively utilized in thrombosis research . This antibody Abciximab antibody fragment specifically targets the glycoprotein IIb/IIIa receptor on thrombocytes , blocking platelet aggregation . As a result, it's frequently investigated as a tool to examine the processes underlying coagulation and to assess the efficacy of antiplatelet therapies. Distribution is typically controlled to academic settings.
```
Abciximab Drug Research: Utilizing C7E3 and The 143653-53-6 Substance in Research Investigations
Ongoing studies into abciximab, a antiplatelet agent, frequently incorporates the monoclonal protein C7E3 and the substance identified as 143653-53-6. These tools are crucial for examining abciximab's biological activity, determining its effectiveness in experimental conditions, and elucidating potential predictors of patient outcome. Further exploration leveraging these precise reagents is predicted to generate valuable insights for optimizing patient care involving cardiovascular conditions.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Analyzing Research Possibilities with Abciximab 143653-53-6 and C7E3
Recent studies suggest that this antiplatelet agent (identified as 143653-53-6) presents significant scientific promise, particularly when combined with C7E3. Early findings indicated that this association might improve clinical responses in several cardiovascular conditions. Further exploration is directed on understanding the exact mechanism of interaction between Abciximab and C7E3, involving analysis of blood clot cohesion and vascular preservation.
- Ongoing research efforts seek to optimize dosing strategies.
- Laboratory approaches are being employed to more assess the hypotheses.
- Patient trials will be necessary to fully assess patient benefit.
```
Abciximab (C7E3) for Research: Specifications and Specifications (143653-53-6)
Researchers seeking this antibody for in vitro research should rigorously evaluate purity and documented specifications . Material 143653-53-6 is typically provided as a freeze-dried powder and thorough analytical data including assessment by LC-MS, potency assays, and endotoxin testing are available. Confirm the manufacturer's documentation outlines acceptable ranges for contaminants and conforms to all QC standards .
High-Purity C7E3 Details & Stock
Acquiring analytical-grade Abciximab, specifically referencing the molecule C7E3 and identified by the product number 143653-53-6, requires careful consideration of its manufacturer. This glycoprotein is commonly utilized in in vitro experiments, particularly those related to platelet aggregation and thrombosis . Existing sources offer this substance in varying volumes, typically ranging from g to larger bulk supplies. Kindly recommend reviewing the documentation of testing to verify integrity and suitability for your specific use . Furthermore , confirm the expiration date before obtaining to maintain ideal performance .
- Common Purity: >95%
- Keeping Conditions: -20°C and suitable conditions
- Application : Platelet Adhesion Suppression Studies